SoulMedX
Oral Drug Dosage Precision
Health Tech & Life Sciences
Non Active, Jan 2025 ceased to operate
Company Overview
Snapshot
Founded in July 2018 by Eran Katz and Dr. Moshe Brand, SoulMedX operates with 1–10 employees. The company ceased operations in January 2025.
Business overview
SoulMedX developed an AI-powered system designed for the precise dosage personalization of oral drugs, enabling remote adjustment based on patient behavior. This solution combines artificial intelligence, big data, and flexible dispensing technologies to serve the digital healthcare and patient engagement sectors within the broader Health Tech & Life Sciences industry.
Log in to access full profile ›Company Intelligence Q&A
- What is SoulMedX's primary focus?
- SoulMedX focuses on enabling precise dosage personalization for oral drugs at patients' homes, leveraging artificial intelligence and big data for remote dosage adjustments based on patient behavior.
- When was SoulMedX founded and by whom?
- SoulMedX was founded in July 2018 by Eran Katz and Dr. Moshe Brand.
- What is the operational status of SoulMedX?
- SoulMedX ceased to operate in January 2025.
- What technology underpins SoulMedX's solution?
- SoulMedX's solution is built upon artificial intelligence, big data analytics, and flexible dispensing technologies to personalize oral drug dosages.
- In which sectors does SoulMedX primarily operate?
- SoulMedX operates within the Health Tech & Life Sciences sector, specifically focusing on digital healthcare and patient engagement.